These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 24102134)

  • 1. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
    Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
    J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of the First-in-Class G9a/GLP PROTAC Degrader.
    Velez J; Han Y; Yim H; Yang P; Deng Z; Park KS; Kabir M; Kaniskan HÜ; Xiong Y; Jin J
    J Med Chem; 2024 Apr; 67(8):6397-6409. PubMed ID: 38602846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells.
    Vedadi M; Barsyte-Lovejoy D; Liu F; Rival-Gervier S; Allali-Hassani A; Labrie V; Wigle TJ; Dimaggio PA; Wasney GA; Siarheyeva A; Dong A; Tempel W; Wang SC; Chen X; Chau I; Mangano TJ; Huang XP; Simpson CD; Pattenden SG; Norris JL; Kireev DB; Tripathy A; Edwards A; Roth BL; Janzen WP; Garcia BA; Petronis A; Ellis J; Brown PJ; Frye SV; Arrowsmith CH; Jin J
    Nat Chem Biol; 2011 Jul; 7(8):566-74. PubMed ID: 21743462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
    Liu F; Barsyte-Lovejoy D; Allali-Hassani A; He Y; Herold JM; Chen X; Yates CM; Frye SV; Brown PJ; Huang J; Vedadi M; Arrowsmith CH; Jin J
    J Med Chem; 2011 Sep; 54(17):6139-50. PubMed ID: 21780790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship studies of G9a-like protein (GLP) inhibitors.
    Xiong Y; Li F; Babault N; Wu H; Dong A; Zeng H; Chen X; Arrowsmith CH; Brown PJ; Liu J; Vedadi M; Jin J
    Bioorg Med Chem; 2017 Aug; 25(16):4414-4423. PubMed ID: 28662962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase.
    Xiong Y; Li F; Babault N; Dong A; Zeng H; Wu H; Chen X; Arrowsmith CH; Brown PJ; Liu J; Vedadi M; Jin J
    J Med Chem; 2017 Mar; 60(5):1876-1891. PubMed ID: 28135087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
    Chen WL; Wang ZH; Feng TT; Li DD; Wang CH; Xu XL; Zhang XJ; You QD; Guo XK
    Bioorg Med Chem; 2016 Nov; 24(22):6102-6108. PubMed ID: 27720557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G9a - An Appealing Antineoplastic Target.
    Chen WL; Sun HP; Li DD; Wang ZH; You QD; Guo XK
    Curr Cancer Drug Targets; 2017; 17(6):555-568. PubMed ID: 27174055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.
    Katayama K; Ishii K; Tsuda E; Yotsumoto K; Hiramoto K; Suzuki M; Yasumatsu I; Igarashi W; Torihata M; Ishiyama T; Katagiri T
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127475. PubMed ID: 32781218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer.
    Shi Y; Shen Q; Long R; Mao Y; Tong S; Yang Y; Gao J; Zhou H; Chen Y; Zhou B
    J Med Chem; 2024 Aug; 67(15):13271-13285. PubMed ID: 39041067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors.
    Yang C; Li B; Feng Z; Li H; Yang H; Yang Z; Liu L; Shi Q; Wang H; Chen ZZ; Huang X; Wang J; Wang Y
    J Med Chem; 2024 Sep; 67(18):16072-16087. PubMed ID: 39008565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properly substituted analogues of BIX-01294 lose inhibition of G9a histone methyltransferase and gain selective anti-DNA methyltransferase 3A activity.
    Rotili D; Tarantino D; Marrocco B; Gros C; Masson V; Poughon V; Ausseil F; Chang Y; Labella D; Cosconati S; Di Maro S; Novellino E; Schnekenburger M; Grandjenette C; Bouvy C; Diederich M; Cheng X; Arimondo PB; Mai A
    PLoS One; 2014; 9(5):e96941. PubMed ID: 24810902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells.
    Cao YP; Sun JY; Li MQ; Dong Y; Zhang YH; Yan J; Huang RM; Yan X
    Acta Pharmacol Sin; 2019 Aug; 40(8):1076-1084. PubMed ID: 30765842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
    Lenstra DC; Al Temimi AHK; Mecinović J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1234-1238. PubMed ID: 29519735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a.
    Liu F; Chen X; Allali-Hassani A; Quinn AM; Wasney GA; Dong A; Barsyte D; Kozieradzki I; Senisterra G; Chau I; Siarheyeva A; Kireev DB; Jadhav A; Herold JM; Frye SV; Arrowsmith CH; Brown PJ; Simeonov A; Vedadi M; Jin J
    J Med Chem; 2009 Dec; 52(24):7950-3. PubMed ID: 19891491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment.
    Chen X; Skutt-Kakaria K; Davison J; Ou YL; Choi E; Malik P; Loeb K; Wood B; Georges G; Torok-Storb B; Paddison PJ
    Genes Dev; 2012 Nov; 26(22):2499-511. PubMed ID: 23105005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery of novel histone lysine methyltransferase G9a inhibitors (part 1): molecular design based on a series of substituted 2,4-diamino-7- aminoalkoxyquinazoline by molecular-docking-guided 3D quantitative structure-activity relationship studies.
    Feng T; Wang H; Zhang X; Sun H; You Q
    Med Chem; 2014 Jun; 10(4):426-40. PubMed ID: 24151879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.
    Liu F; Chen X; Allali-Hassani A; Quinn AM; Wigle TJ; Wasney GA; Dong A; Senisterra G; Chau I; Siarheyeva A; Norris JL; Kireev DB; Jadhav A; Herold JM; Janzen WP; Arrowsmith CH; Frye SV; Brown PJ; Simeonov A; Vedadi M; Jin J
    J Med Chem; 2010 Aug; 53(15):5844-57. PubMed ID: 20614940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.
    Wei J; Shi Q; Li B; Yang H; Liu L; Zhou R; Feng Z; Yang Z; Zhan J; Xiong XF; Huang X; Wang Y
    J Med Chem; 2024 Sep; 67(18):16056-16071. PubMed ID: 39230932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.
    Feng Z; Yang C; Zhang Y; Li H; Fang W; Wang J; Nie Y; Wang CY; Liu Z; Jiang Z; Wang J; Wang Y
    J Med Chem; 2023 Jun; 66(12):8086-8102. PubMed ID: 37268593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.